CRISPR/Cas9 mRNA
Showing 1 - 25 of 874
Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection Trial in Shanghai (BD111 Adult single group Dose)
Completed
- Viral Keratitis
- +3 more
- BD111 Adult single group Dose
-
Shanghai, Shanghai, ChinaEye & Ent Hospital of Fudan University
Aug 20, 2022
Gene Editing as a Therapeutic Approach for Rett Syndrome
Recruiting
- Rett Syndrome
- Gene editing in vitro
-
Siena, ItalyUniversity of Siena
Feb 13, 2023
Carbapenem-Resistant Enterobacteriaceae Infection Trial in Jinan (CAZ/AVI plus Aztreonam, Conventional treatment)
Recruiting
- Carbapenem-Resistant Enterobacteriaceae Infection
- CAZ/AVI plus Aztreonam
- Conventional treatment
-
Jinan, Shandong, ChinaMingju Hao
Apr 29, 2023
Beta-Thalassemia, Thalassemia, Hematologic Diseases Trial (CTX001)
Not yet recruiting
- Beta-Thalassemia
- +6 more
- CTX001
- (no location specified)
Jul 26, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Worldwide (CTX001)
Active, not recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Stanford, California
- +11 more
Nov 30, 2022
Transfusion Dependent Beta-Thalassaemia Trial in Guangzhou, Shenzhen, Tianjin (ET-01)
Active, not recruiting
- Transfusion Dependent Beta-Thalassaemia
- ET-01
-
Guangzhou, Guangdong, China
- +3 more
May 9, 2022
NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +5 more
- Fludarabine
- +4 more
-
Duarte, California
- +1 more
Dec 7, 2022
COVID-19 Respiratory Infection Trial (PD-1 and ACE2 Knockout T Cells)
Not yet recruiting
- COVID-19 Respiratory Infection
- PD-1 and ACE2 Knockout T Cells
- (no location specified)
Aug 13, 2021
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)
Recruiting
- Clear Cell Renal Cell Carcinoma
- +4 more
- CTX131
-
Nashville, TennesseeResearch Site 1
Mar 21, 2023
Relapsed/Refractory Acute Myeloid Leukemia (AML) Trial in Dresden, Heidelberg (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated
Not yet recruiting
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion
- Gemtuzumab Ozogamicin
-
Dresden, Germany
- +1 more
Dec 20, 2022
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
Gastrointestinal Epithelial Cancer, Gastrointestinal Tumors, Cancer of Gastrointestinal Tract Trial in Minneapolis
Recruiting
- Gastrointestinal Epithelial Cancer
- +10 more
- Cyclophosphamide
- +3 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Aug 20, 2021
A Long-term Follow-up Study in Subjects Who Received CTX001
Enrolling by invitation
- Beta-Thalassemia
- +6 more
- CTX001
-
New York, New York
- +12 more
Nov 18, 2022
Solid Tumor, Adult Trial in Beijing (anti-mesothelin CAR-T cells)
Unknown status
- Solid Tumor, Adult
- anti-mesothelin CAR-T cells
-
Beijing, ChinaBiotherapeutic Department and Hematology Department of Chinese P
Aug 6, 2020
T Cell Lymphoma Trial in Australia, Canada, United States (CTX130)
Recruiting
- T Cell Lymphoma
- CTX130
-
Duarte, California
- +9 more
May 16, 2022
Multiple Myeloma Trial in Worldwide (CTX120)
Active, not recruiting
- Multiple Myeloma
- CTX120
-
Chicago, Illinois
- +9 more
Jul 14, 2022
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn Trial in Nashville (CTX001)
Recruiting
- Beta-Thalassemia
- +4 more
- CTX001
-
Nashville, Tennessee
- +5 more
Feb 2, 2023
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance Trial in Nashville (CTX001)
Recruiting
- Sickle Cell Disease
- +4 more
- CTX001
-
Philadelphia, Pennsylvania
- +3 more
Jan 24, 2023
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy,
Recruiting
- Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
- +2 more
- NTLA-2001
-
Paris, France
- +3 more
Nov 29, 2022
Hereditary Angioedema Trial in Amsterdam, Auckland, Cambridge (Biological NTLA-2002, Normal Saline IV Administration)
Recruiting
- Hereditary Angioedema
- Biological NTLA-2002
- Normal Saline IV Administration
-
Amsterdam, Netherlands
- +2 more
Jul 18, 2022
Thalassemia, Beta, Thalassemia Major Trial in Tianjin (VGB-Ex01)
Not yet recruiting
- Thalassemia, Beta
- Thalassemia Major
- VGB-Ex01
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Sep 11, 2023
Stem Cells in NF1 Tumors of the Central Nervous System
Suspended
- Neurofibromatosis Type 1
- Tumors of the Central Nervous System
- Collection of Stem Cells
-
Washington, District of ColumbiaChildren's National Medical Center
Mar 8, 2022
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma Trial in Worldwide (CTX110)
Recruiting
- B-cell Malignancy
- +3 more
- CTX110
-
Los Angeles, California
- +27 more
May 6, 2022